CORE--BLOOD PRODUCTS

核心--血液制品

• 批准号: 6494854
• 负责人: Shelly Heimfeld
• 金额: $ 20.94万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6494854
• 关键词: biomedical facility; biotechnology; blood cells; blood preservation; bone marrow; bone marrow preservation; cell population study; clinical chemistry; cryoscience; flow cytometry; hematopoietic stem cells; tissue /cell preparation; tissue resource /registry

The Cell Processing Core will provide critical resources that will circumvent many of the technical problems that limit progress in the isolation, molecular characterization, functional analysis and genetic modification of stem cells. Primary among these limitations is an inability to obtain sufficient quantities for purified stem cells needed for experimentation and optimization of the ex-vivo conditions required for efficient transduction. This Core will address that limitation by providing three specific functions. (1) The Core will provide SCOR investigators with access to large quantities of purified stem cells for in vitro studies for large animal model testing, and for clinical trial usage. Taking advantage of the instrumentation and expertise available from within the FHCRC Cryobiology Laboratory, the Core will provide clinical-grade stem cell enrichment for components obtained from both human and large animals such as dogs and primates. (2) The Core will characterize enriched and transduced stem cell populations by performing 2 and 3 color flow cytometric determinations and quantitative CFC and LTC-IC assay. These diagnostic services will provide SCOR investigators with the ability to quality control results from the component processing described above, and to determine efficiencies of gene transduction in the various stem/progenitor cell compartments. (3) The Core will operate a donor recruitment program and a Repository of Cryopreserved Specimens. Established protocols permit collection by apheresis of large quantities of cells from G-CSF-treated or untreated donors, which will provide clinical quantities of cells for the SCOR projects involving human cells. Similarly, the Core will collect and distribute small quantities of human bone marrow. The Repository contains stored marrow of PBSC components from normal donors or decreased patients where permission to use these products for research has been obtained. This Repository will serve as source material for SCOR investigators to obtain specific cells for their research studies. This ability to process and isolate large numbers of cells will greatly enhance and facilitate research studies in the areas of stem cell biology, and to develop and test improvements to gene therapy approaches for the treatment of hematopoietic disorders.

细胞处理核心将提供关键资源，克服许多限制干细胞分离、分子表征、功能分析和遗传修饰进展的技术问题。这些限制中最主要的是无法获得足够数量的纯化干细胞，以进行实验和优化有效转导所需的离体条件。该核心将通过提供三个特定功能来解决该限制。 (1) Core 将为 SCOR 研究人员提供大量纯化干细胞，用于大型动物模型测试的体外研究和临床试验用途。利用 FHCRC 低温生物学实验室提供的仪器和专业知识，该核心将为从人类和大型动物（例如狗和灵长类动物）获得的成分提供临床级干细胞富集。 (2) Core 将通过进行 2 色和 3 色流式细胞术测定以及定量 CFC 和 LTC-IC 测定来表征富集和转导的干细胞群。这些诊断服务将为 SCOR 研究人员提供对上述成分处理结果进行质量控制的能力，并确定各种干细胞/祖细胞区室中基因转导的效率。 (3) 核心将运营捐赠者招募计划和冷冻保存标本储存库。已建立的协议允许通过单采术从经 G-CSF 处理或未经处理的供体中收集大量细胞，这将为涉及人类细胞的 SCOR 项目提供临床数量的细胞。同样，核心将收集和分发少量的人类骨髓。该存储库包含来自正常捐赠者或减少患者的储存的 PBSC 成分骨髓，这些患者已获得使用这些产品进行研究的许可。该存储库将作为 SCOR 研究人员获取特定细胞用于其研究的源材料。这种处理和分离大量细胞的能力将极大地增强和促进干细胞生物学领域的研究，并开发和测试用于治疗造血疾病的基因治疗方法的改进。